DACOPLICE 30mg Tab
Brand Name: Dacoplice®
Composition: Dacomitinib 30mg
Manufacturer: Pfizer
Product Description
Medical Info
Dacoplice® 30 mg contains Dacomitinib, an advanced antineoplastic medication categorized as a tyrosine kinase inhibitor (TKI). Developed by Pfizer, this targeted therapy is primarily indicated as a first-line treatment for adults diagnosed with metastatic non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) mutations. By precisely binding to and blocking the abnormal proteins driving malignant cellular division, Dacoplice® effectively slows or halts the proliferation and spread of tumor cells. Administered orally under strict oncological supervision, it plays a vital role in modern precision oncology regimens to manage advanced disease progression.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
